Amgen Inc. $AMGN Shares Sold by Modera Wealth Management LLC

Modera Wealth Management LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 2.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 102,431 shares of the medical research company’s stock after selling 2,080 shares during the period. Modera Wealth Management LLC’s holdings in Amgen were worth $33,527,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of AMGN. Capital World Investors grew its holdings in shares of Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after acquiring an additional 1,935,876 shares during the period. National Bank of Canada FI grew its holdings in shares of Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after acquiring an additional 863,216 shares during the period. Van ECK Associates Corp grew its holdings in shares of Amgen by 71.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock worth $383,254,000 after acquiring an additional 567,400 shares during the period. Fisher Asset Management LLC raised its position in shares of Amgen by 91.6% during the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock worth $221,607,000 after purchasing an additional 375,463 shares during the last quarter. Finally, Danske Bank A S acquired a new position in shares of Amgen during the 3rd quarter worth approximately $101,076,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Down 1.5%

Shares of AMGN opened at $342.57 on Tuesday. The stock has a fifty day moving average of $363.51 and a two-hundred day moving average of $333.65. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a market capitalization of $184.67 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 3.45 and a beta of 0.47. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is 70.84%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on AMGN shares. Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Sanford C. Bernstein downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a research report on Tuesday, January 20th. Citigroup lifted their price objective on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Rothschild & Co Redburn lifted their price objective on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Finally, Leerink Partners restated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.